3 results
Approved WMOCompleted
Objective: to investigate if Ulipristal is non-inferior to GnRH in terms of intra-operative blood-loss (primary outcome), surgical time, surgical ease, complications, quality of life and costs.
Approved WMOCompleted
1. To define the optimal pharmacokinetic tracer model for [18F]afatinib. 2. To determine the optimal simplified measure for quantifying tumor [18F]afatinib uptake 3. To assess [18F]afatinib uptake differences between patients (1) with wild type EGFR…
Approved WMOCompleted
To assess the proportion of patients who are alive without disease progression at 6 months based on local investigator assessment per RECIST v1.1 in cohort A and cohort B 13-03-2019: new cohort added (3 cohorts now)